Albuminuria - Short Notes

Definition

Albuminuria refers to the abnormal excretion of albumin in the urine exceeding 30 mg/day (or urine albumin-to-creatinine ratio [ACR] > 30 mg/g). Normal urinary albumin excretion is less than 30 mg/day, with the normal ACR in young adults being less than 10 mg/g. It is a key biomarker of glomerular and tubular dysfunction, and a defining criterion for chronic kidney disease (CKD).

National Kidney Foundation Primer on Kidney Diseases, 8e, p. 66
Brenner and Rector's The Kidney, p. 1175

Normal Urinary Protein Physiology

Total urinary protein < 150 mg/day under normal conditions (primarily uromodulin / Tamm-Horsfall protein)
Albumin < 30 mg/day is excreted normally
The glomerular filtration barrier (fenestrated endothelium + GBM + podocyte slit diaphragms) provides a size- and charge-selective barrier. Albumin (70 kD, anionic, pI ~4.5, sieving coefficient 0.0006) is largely excluded
4-8 g/day is actually filtered but nearly all is reabsorbed by the proximal convoluted tubule (PCT) via receptor-mediated endocytosis (megalin/cubilin system)

KDIGO Classification

Category	Old Term	AER (mg/24 h)	ACR (mg/g)	ACR (mg/mmol)
A1 - Normal to mildly increased	Normoalbuminuria	< 30	< 30	< 3
A2 - Moderately increased	Microalbuminuria	30-300	30-300	3-30
A3 - Severely increased	Macroalbuminuria	> 300	> 300	> 30

Note: The terms microalbuminuria and macroalbuminuria have been officially abandoned in favor of the above terminology. ACR > 2000 mg/g is accompanied by signs/symptoms of nephrotic syndrome (edema, hypoalbuminaemia, hypercholesterolaemia).

Comprehensive Clinical Nephrology, 7th Edition, p. 1618
Brenner and Rector's The Kidney, p. 1175

Pathophysiology / Mechanisms

Albuminuria arises from three main mechanisms:

Glomerular proteinuria - Defects in the size- and charge-selective glomerular filtration barrier (GBM, podocyte nephrin/podocin). Occurs with inflammation, scarring, deposition, or genetic conditions. Albuminuria typically exceeds 400 mg/day. Seen in glomerulonephritis, diabetic nephropathy, amyloidosis.
Tubular proteinuria - Impaired PCT reabsorption of filtered proteins. Produces low-molecular-weight proteinuria (beta-2 microglobulin, retinol-binding protein). Seen in tubulointerstitial nephritis, heavy-metal toxicity, Dent disease, Lowe syndrome. NOT detected by standard dipstick.
Overflow proteinuria - Excessive plasma protein load overwhelms tubular reabsorption (e.g., Bence Jones proteins in multiple myeloma, myoglobin in rhabdomyolysis).

Epidemiology

Albuminuria > 30 mg/day is present in 6.7% of the US general population
Prevalence in diabetes: 28.8%
Prevalence in hypertension: 16%
Prevalence increases after age 40 (3.3% with normal GFR have persistent albuminuria)
50% more common in women than men (9.7% vs. 6.1%)
More common in individuals of African and Mexican ancestry (due to higher prevalence of diabetes, hypertension, glomerular disease, and APOL1 risk alleles)
National Kidney Foundation Primer on Kidney Diseases, 8e, p. 66

Clinical Significance

CKD Diagnosis

Albuminuria > 30 mg/day persisting for > 3 months defines CKD regardless of eGFR level. KDIGO uses a combined GFR-albuminuria staging system (G1-G5 + A1-A3) to risk-stratify patients.

Cardiovascular Risk

Albuminuria is a continuous, independent risk factor for cardiovascular mortality and ESRD with no lower threshold - even after adjusting for eGFR and other established risk factors. Both the NKF and AHA include albuminuria as a risk factor for renal and cardiovascular disease.

CKD Progression

Any degree of albuminuria is associated with increased risk of DKD progression and CVD
Albuminuria predicts faster eGFR decline; high ACR at baseline correlates with doubling of serum creatinine in RAAS-treated patients (IDNT, RENAAL trials)
Even A2 (moderately increased) albuminuria may spontaneously remit in some patients with T2D

AKI Risk

Elevated uACR (> 300 mg/g) carries a 2.73-fold higher risk of hospitalization for AKI (large meta-analysis, 8 cohorts, 1.28 million subjects)
Higher preoperative ACR categories predict post-cardiac surgery AKI (TRIBE-AKI cohort)

Measurement and Evaluation

Preferred test: Spot urine ACR (first-void or early morning specimen preferred to reduce orthostatic variation)

Confirmatory test: Timed 24-hour urine albumin excretion rate (AER)

At least 3 separate samples over 3+ months are required to confirm persistent albuminuria and reduce intraindividual variation
KDIGO recommends initial evaluation with spot urine ACR; alternatives include spot PCR (protein-to-creatinine ratio) or urine dipstick

Measure	A1	A2	A3
AER (mg/24 h)	< 30	30-300	> 300
ACR (mg/g)	< 30	30-300	> 300
PCR (mg/g)	< 150	150-500	> 500
Dipstick	Negative/trace	Negative-positive	Positive or greater

National Kidney Foundation Primer on Kidney Diseases, 8e, p. 484

Causes of Albuminuria

Category	Examples
Glomerular	Diabetic nephropathy, IgA nephropathy, minimal change disease, FSGS, membranous nephropathy, lupus nephritis
Tubular	Tubulointerstitial nephritis, heavy-metal nephropathy, Fanconi syndrome
Systemic/vascular	Hypertension, heart failure, pre-eclampsia
Transient (non-pathological)	Fever, exercise, orthostatic (postural) proteinuria, UTI
Overflow	Multiple myeloma, rhabdomyolysis

Treatment Approach (Reducing Albuminuria)

RAAS blockade - ACE inhibitors and ARBs are first-line in both diabetic and non-diabetic proteinuric CKD; independently reduce intraglomerular pressure and albuminuria regardless of BP effect
SGLT2 inhibitors - Reduce albuminuria, slow eGFR decline, and reduce risk of kidney failure and CVD in patients with albuminuric diabetic or non-diabetic CKD (CREDENCE, DAPA-CKD, EMPA-KIDNEY trials)
GLP-1 receptor agonists - Also reduce albuminuria in diabetic kidney disease
BP control - Target < 130/80 mmHg in proteinuric CKD
Glycaemic control - Especially in diabetic nephropathy
Dietary protein restriction - May reduce proteinuria load

Goldman-Cecil Medicine, p. 2873
Comprehensive Clinical Nephrology, 7th Edition

Key Takeaway Points

Albuminuria is both a marker of kidney damage and an independent risk factor for CKD progression, AKI, and cardiovascular events
KDIGO categorizes it as A1/A2/A3; old terms "micro/macroalbuminuria" are abandoned
Spot urine ACR is the standard measurement tool; confirm with 3 samples > 3 months apart
At A2 level (ACR 30-300 mg/g), intervention with RAAS blockade can slow or even reverse progression
ACR > 2000 mg/g signals nephrotic-range disease

This is a shared conversation. Sign in to Orris to start your own chat.